A possible method using baseline hormonal levels to prescribe the appropriate oral therapeutic radioiodine dosage for Graves' disease

• Published in: Annals of nuclear medicine Vol. 21; no. 8; pp. 471 - 476
• Main Authors: Nakajo, Masayuki, Tsuchimochi, Shinsaku, Jinguji, Megumi, Tanabe, Hiroaki, Umanodan, Tomoichi, Nakabeppu, Yoshiaki
• Format: Journal Article
• Language: English
• Published: Japan Springer Nature B.V 01-10-2007
• Subjects: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Graves Disease - blood; Graves Disease - diagnosis; Graves Disease - radiotherapy; Humans; Iodine Radioisotopes - administration & dosage; Male; Middle Aged; Prognosis; Radiopharmaceuticals - administration & dosage; Regression analysis; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Statistics as Topic; Thyroid gland; Thyroid Hormones - blood; Treatment Outcome
• DOI: 10.1007/s12149-007-0053-8
• EISSN: 1864-6433
• ISSN: 0914-7187

The purpose of this study was to retrospectively examine the correlations of hormonal ratios with radioiodine I-131 therapeutic parameters and the potentiality of prescribing the therapeutic I-131 target dosage for an individual patient with Graves' disease using baseline serum levels of thyroid hormones.
Serum T3, T4, and FT4 levels 6 and 12 months after I-131 therapy/baseline levels (hormonal ratios) were calculated for a total of 68 therapeutic courses in 57 patients with Graves' disease. The therapeutic parameters were absorbed dose (Gy), dose concentration (microCi/g) and oral dose (mCi). Linear regression analysis was performed for correlating hormonal ratios (X) and therapeutic parameters (Y).
Significant (P<0.05) negative correlations of the hormonal ratios were observed with absorbed dose (R -0.50 for T3, -0.61 for T4, and -0.46 for FT4 at 6 months, and -0.29 for T3, -0.44 for T4 at 12 months) and dose concentration (R -0.57 for T3, -0.58 for T4, and -0.49 for FT4 at 6 months and -0.27 for T3, -0.27 for T4 at 12 months), but not with oral dose at 6 months and 12 months or the absorbed dose and dose concentration for FT4 at 12 months. The correlations were higher at 6 months than at 12 months and in serum T4 than in serum T3 and FT4. The formulae for serum T4 at 6 months were as follows: Y (Gy)=109-53X and Y (microCi/g)=109-52X.
These results suggest that the hormonal ratios are significantly correlated with the absorbed dose and dose concentration. The formulae for serum T4 at 6 months may serve to prescribe the individual oral dosage for Graves' disease, although the correlation coefficients are about -0.6.